KIT and gastrointestinal stromal tumor: Several small molecule compounds targeting KIT and other tyrosine kinases, such as imatinib (12, 13), sunitinib (17), regorafenib (18) and ripretinib (19) have shown efficacy in advanced GIST and have been approved for the treatment of advanced GIST.